about
Analysis to Estimate Genetic Variations in the Idarubicin-Resistant Derivative MOLT-3.Bayesian model of signal rewiring reveals mechanisms of gene dysregulation in acquired drug resistance in breast cancerUpregulation of miR-181c contributes to chemoresistance in pancreatic cancer by inactivating the Hippo signaling pathwayYAP induces cisplatin resistance through activation of autophagy in human ovarian carcinoma cells.Cullin 4A (CUL4A), a direct target of miR-9 and miR-137, promotes gastric cancer proliferation and invasion by regulating the Hippo signaling pathway.Verteporfin suppresses cell survival, angiogenesis and vasculogenic mimicry of pancreatic ductal adenocarcinoma via disrupting the YAP-TEAD complex.Hypoxia induces oncogene yes-associated protein 1 nuclear translocation to promote pancreatic ductal adenocarcinoma invasion via epithelial-mesenchymal transition.TAZ induces lung cancer stem cell properties and tumorigenesis by up-regulating ALDH1A1Regulation of sensitivity of tumor cells to antitubulin drugs by Cdk1-TAZ signalling.Hippo Component TAZ Functions as a Co-repressor and Negatively Regulates ΔNp63 Transcription through TEA Domain (TEAD) Transcription Factor.Integrated analysis profiles of long non-coding RNAs reveal potential biomarkers of drug resistance in lung cancer.Culture on 3D Chitosan-Hyaluronic Acid Scaffolds Enhances Stem Cell Marker Expression and Drug Resistance in Human Glioblastoma Cancer Stem Cells.Downregulation of miR-874-3p promotes chemotherapeutic resistance in colorectal cancer via inactivation of the Hippo signaling pathway.Soft-shelled turtle peptide modulates microRNA profile in human gastric cancer AGS cells.Cysteine residues are essential for dimerization of Hippo pathway components YAP2L and TAZ.Long-Term Exposure to Imatinib Mesylate Downregulates Hippo Pathway and Activates YAP in a Model of Chronic Myelogenous Leukemia.The Hippo Pathway: Immunity and Cancer.Inhibition of yes-associated protein suppresses brain metastasis of human lung adenocarcinoma in a murine model.YAP/TAZ Activation as a Target for Treating Metastatic Cancer.A LATS biosensor screen identifies VEGFR as a regulator of the Hippo pathway in angiogenesis.Individualized predictive signatures for 5-fluorouracil-based chemotherapy in right- and left-sided colon cancer.Huaier Augmented the Chemotherapeutic Sensitivity of Oxaliplatin via Downregulation of YAP in Hepatocellular CarcinomaMechanoregulation and pathology of YAP/TAZ via Hippo and non-Hippo mechanisms
P2860
Q30396832-37D51FD7-BD37-4CAD-9C35-7C4BA7859318Q36306149-014B0B4E-9C30-4BD5-BE60-F7B95BB5FB70Q36689006-A59A4293-464F-44A8-913D-8C2C3C5D1087Q36726132-2A035822-4E72-453D-8C38-176CAB8B2F3AQ36962867-1B1CE50B-9D34-4818-AA29-E8B9C047FCCAQ37735656-CEB90F0F-0CF0-4F58-9E26-2ACA5244266BQ38704712-656029EF-F5AC-40DA-AD65-6D931B9B2D57Q38729543-94A78B27-C9C2-40B5-8508-623A36E29B3EQ38852131-3325D58A-88B5-4305-9D49-6458E47EB2C8Q38872721-B2918F60-E98B-4372-96F3-EA169A51C8C9Q41846396-487E6B90-BDF4-445D-8D34-1570B03421E4Q45893116-A9CBBE79-21FF-44C8-8C18-379BFC00ED9DQ48629122-63B8DB45-3421-4533-A89B-315B37BAE21DQ49714381-6F1F87A9-B935-49D9-AA34-73B43599DA90Q50308570-2E2A2127-30BA-4E08-BDA8-BA14D7141AB1Q51181111-C2324830-FC96-4316-9277-640863A0E823Q52621407-6296790A-7DAE-45E0-9F7D-F56611545248Q52633438-0421C6C9-20AC-4444-B272-FEF014D7492CQ54977387-224C7FE4-2125-4BA2-A98B-108849AEA601Q54982188-CFD22A39-68D3-4C7F-9EC8-3257D24E9E5AQ55315465-8870899E-B7DD-404C-B86E-73CAFA81C027Q58576706-492DF138-644B-48AC-ADB4-B92ADD2156F0Q58787445-D3C965C8-AFD2-452C-A5A6-B71294407B2A
P2860
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
2014年學術文章
@zh
2014年學術文章
@zh-hant
name
The Hippo pathway in chemotherapeutic drug resistance.
@en
type
label
The Hippo pathway in chemotherapeutic drug resistance.
@en
prefLabel
The Hippo pathway in chemotherapeutic drug resistance.
@en
P2860
P356
P1476
The Hippo pathway in chemotherapeutic drug resistance.
@en
P2093
Xiaolong Yang
Yulei Zhao
P2860
P304
P356
10.1002/IJC.29293
P577
2014-10-27T00:00:00Z